China
Africa
Explore chapters and articles related to this topic
Vascular anomalies
Published in Mark Davenport, James D. Geiger, Nigel J. Hall, Steven S. Rothenberg, Operative Pediatric Surgery, 2020
Eileen M. Duggan, Steven J. Fishman
The International Society for the Study of Vascular Anomalies (ISSVA) has accepted the terminology proposed by Mulliken in 1982 that classifies lesions broadly into vascular tumors and vascular malformations (Table 85.1).2,3 Vascular tumors are proliferative lesions that range from benign to malignant. Vascular malformations consist of vessels that formed abnormally during development. They are classified by the type of vascular channel of which they are comprised, i.e. capillary (C), lymphatic (L), venous (V), or arterial (A). Malformations (M) can be combinations of more than one type (e.g. CLM) and they can be associated with non-vascular anomalies such as in Klippel–Trenaunay syndrome (CLVM + limb overgrowth), Parkes Weber syndrome (CAVM + limb overgrowth), CLOVES (congenitallipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal anomalies)4 and Sturge–Weber syndrome (facial and leptomeningeal CM + eye anomalies ± bone and/or soft-tissue overgrowth).
Congenital neck lumps
Published in Neeraj Sethi, R. James A. England, Neil de Zoysa, Head, Neck and Thyroid Surgery, 2020
Vascular malformations are a result of defective development of vascular structures, resulting in an abnormal number of or abnormally sized vessels, which may be arterial, venous, lymphatic or a combination. Vascular malformations are classified into high- or low-flow malformations.
How much is too much for arteriovenous malformation management?
Published in Byung-Boong Lee, Peter Gloviczki, Francine Blei, Jovan N. Markovic, Vascular Malformations, 2019
Vascular malformations could occur when there is a defect in either an early or late phase of vascular development. Previous studies on AVM suggest that multiple pathways rather than a single pathway are involved in AVM pathogenesis. In animal studies, various signaling molecules were reported to be involved in the early and later stages of vascular development.8, 9
Novel treatment of recurrent orbital venolymphatic malformation with sirolimus and rivaroxaban
Published in Orbit, 2022
Boonkit Purt, Harkaran S. Rana, Todd D. Whitescarver, Eva Chou
The patient is a 20-year-old male with congenital orbital and intracranial venolymphatic malformations with complications of seizures, nystagmus, amblyopia, and developmental delay. His vascular malformations were initially treated with several surgeries. Prior to age one, he underwent two major surgeries consisting of craniotomies and orbitotomies with lesion debulking. At six and eight years of age, he underwent a third and fourth debulking surgery with partial resection of frontal lobe and cerebellar regions. At nine years of age, he underwent at least two eyelid surgeries and lymphatic cyst drainages with intralesional sclerotherapy with bleomycin. A repeat attempt at intralesional sclerotherapy was performed less than a year later with doxycycline and interferon. Pulses of systemic prednisone every 3–4 months were used to control his flares until 17 years of age, when he again underwent intralesional sclerotherapy with bleomycin and doxycycline, which, with intermittent prednisone pulses, was again sufficient to control his symptoms for the next three years.
MRI-guided endovascular intervention: current methods and future potential
Published in Expert Review of Medical Devices, 2022
Bridget F. Kilbride, Kazim H. Narsinh, Caroline D. Jordan, Kerstin Mueller, Teri Moore, Alastair J. Martin, Mark W. Wilson, Steven W. Hetts
The main therapy for many vascular diseases, along with drug treatment, is image-guided endovascular intervention. Endovascular interventions are typically performed by inserting a catheter into the femoral artery, which is then navigated under x-ray guidance through the vasculature to the treatment site. The diseased area may be a portion of the vessel wall that has weakened to form an aneurysm susceptible to hemorrhage, or a vessel may become stenotic or occluded by a plaque or clot. Vessels can also become sites of abnormal growth in the case of vascular malformation. The endovascular intervention may involve catheter-based delivery of an embolic material or therapy drug, or deployment of a medical device, such as a detachable aneurysm coil or stent to allow blood flow through a stenotic vessel. Furthermore, another important treatment application lies in oncology, in which chemotherapy drugs or radiation-emitting particles can be delivered directly to the vascular bed feeding a tumor. Minimally invasive procedures, such as endovascular intervention, continue to replace invasive surgical procedures because of their effectiveness with reduced mortality, morbidity, and strain on hospital resources [1].
Use of percutaneous bleomycin sclerotherapy for orbital lymphatic malformations
Published in Orbit, 2019
Adam M. Hanif, Justin A. Saunders, C. Matthew Hawkins, Ted H. Wojno, Hee Joon Kim
Vascular malformations are categorized into low-flow lesions (e.g. venous, lymphatic, capillary, and mixed malformation) and high-flow lesions (arteriovenous malformations and fistulae). Lymphatic malformations constitute only about 0.5% of all vascular malformations and like most other vascular malformations pose a therapeutic challenge.18 In this study, we performed a 5-year retrospective chart review to survey the clinical findings of patients who presented to Emory University Hospital and Clinics with confirmed diagnoses of orbital lymphatic malformations and their outcomes following treatment with bleomycin sclerotherapy. Our method for performing the sclerotherapy was comparable to what has been described in the literature. With regard to the injection of bleomycin, the lesion cavity was first aspirated such that the total volume of the lymphatic malformation after delivery of bleomycin was no greater than prior to starting the procedure. Because the exact mechanism of bleomycin is not yet entirely understood, the amount of time needed for bleomycin to have its optimal effect remains unknown. Thus, the cavity was not re-aspirated after first injection of bleomycin.